List of Biotech, Pharmaceutical & Life Sciences companies in France - 280

3-D Matrix is a medical device company that offers innovative peptide technology, revolutionising the way healthcare professionals manage oozing bleeding during surgery. Headquartered in Tokyo, Japan, 3-D Matrix has expanded across America, Europe, Middle East and Asia. The company collaborates with many researchers, surgeons, healthcare providers and distributors across the world to continually improve on our product. We keep patient outcome at our heart, operating on three main principles: agility, proactiveness and focus. Follow us on Twitter @3dm_emea Sign up to our newsletter for the latest clinical data and product announcements: https://news.3dmatrix.com/newsletter-subscription

4Moving Biotech is a clinical-stage biopharmaceutical company founded in 2020. We are committed to develop first-in-class breakthrough therapies for the millions of patients suffering from osteoarthritis (OA) in the world. 4Moving Biotech is a subsidiary of 4P-Pharma, an innovation accelerator biotech company.

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

Specialized in cell culture, Abcell-bio has a 10-year background and experience in Stem Cell Research and Development. Abcell-bio team is composed of experts that can advise you for your research projects. Our technical team is trained to produce high-quality products in the fields of hematopoiesis and vascular biology. We can process several cell types extracted from: * Cord Blood: CD34+ cells, CD133+ cells, CD34- cells, MonoNuclear Cells (MNCs), Endothelial Progenitor Cells (EPCs) * Umbilical Cord (Human Umbilical Vein/Arterial Endothelial Cells (HUVEC, HUAEC) We also created Cell Culture Media to match your needs for these particular cell types. Please contact us for more information

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is a potential first-line advanced therapy for moderately to severely active ulcerative colitis designed to enhance the expression of a single micro-RNA, miR-124, which is a natural regulator of the immune response. Abivax’s focus is on indications where existing treatments have left patients with significant unmet needs, and where they believe their drug candidates have the potential to be meaningfully differentiated from currently available therapies.

Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanist ambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: ·      Using renewable raw materials ·      Relocate essential production and secure supply chains ·      Designing biocompatible products less toxic for the environment ·      Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms Because each customer has its own unique story and challenges, we cultivate a multidisciplinary, tailor-made approach. Science, economics, intellectual property, industrial realities: each of our answers is based on the best possible practices. Thanks to our advanced knowledge of micro-organisms, we combine chemistry and biology, paving the way for a more sustainable future. We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference

AB Science is a clinical-stage company designing and developing novel drugs to address diseases with a high unmet medical need, including inflammatory diseases, pathologies affecting peripheral and central nervous system and cancers. Our science is based on a highly integrated research network associating a state-of-the art drug discovery department to the highly valuable knowledge of our scientific committee’s members in order to develop original and innovative therapeutic strategies. This is illustrated by masitinib, our main clinical compound, which was designed as a disrupting mast-cells and glial-cells targeted therapy, through inhibition of key tyrosine kinase targets (c-Kit, CSF1R, FYN, LYN), which is currently developed in four therapeutic areas: neurology (amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s Disease), inflammatory diseases (mastocytosis, severe asthma), oncology (prostate cancer, pancreatic cancer) and viral diseases (Covid-19). AB Science intends to push therapeutic innovation forward with its second clinical compound AB8939 in oncology.

Acobiom is specialized in the identification of new Biomarkers and in the development of innovative Diagnostics in Translational Research and Precision Medicine. The company provides also customized services in genomics, transcriptomics, bioinformatics and biostatistics (data science), thanks to its technology platform and its scientific expertise. For more information about Acobiom, please contact the company by email: busdev@acobiom.com, or visit its website: www.acobiom.com.

ACS Biotech vision is to change the lives of millions of people suffering from osteoarticular pathologies through regenerative medicine and development of new cellular-based products. Our solution for cartilage repair, aims to regenerate articular cartilage damage with our Cartilage gel with only one precise and mini-invasive surgery, practised by specialized orthopaedic surgeons. A few months later, patients could remain their mobility and sportive activities.

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/

Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes. Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis.

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases. At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases should be available to patients of all ages.

Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments. These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology. Two initial drug candidates are already in clinical trials in indications with high unmet medical needs: • AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022. • AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023. Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies. Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.

🚀 Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. By precisely controlling levitated cells with sound waves, our systems handle cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. This technology enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing for the handling of tens of milliliters per minute. Such capabilities are critical for scaling applications from research to clinical and industrial use. 💡Today, we have achieved proof-of-concepts for our contact-free & label-free proprietary technology across multiple cell types & processes. Mitis™, our flagship product, is already used for a wide range of applications, including cell sorting, isolation, concentration & washing, from research to clinical and industrial scale. 🌍Co-founded by pioneers of acoustic levitation & fluid mechanics and a biotech entrepreneur, the company benefits from the support of the European Commission & the French Government and from the commitment of leading investors, notably the European Investment Bank and Seventure Partners.

Affluent Medical est un nouvel acteur français de la medtech ayant pour ambition de devenir un des leaders européens dans les domaines cardiovasculaires et urologiques. Affluent Medical développe des implants innovants mini-invasifs de nouvelle génération pour restaurer des fonctions physiologiques essentielles dans ces domaines : - Kardiozis vise à prévenir les endofuites et les risques de récidive de l'anévrisme de l'aorte abdominale permettant aux patients de vivre plus sereinement face à un risque de rupture imprévisible ; - Kalios et Epygon visent à offrir des traitements chirurgicaux plus physiologiques pour la réparation ou le remplacement de la valve mitrale du cœur. Kalios permet de traiter les fuites résiduelles post-opératoire et l'insuffisance mitrale récurrente sans avoir à réopérer les patients. Epygon est aujourd'hui la seule valve transcathéter en développement permettant de restaurer les flux sanguins naturels et de sauvegarder le ventricule gauche. - Enfin, Artus est le premier sphincter artificiel activable électroniquement pour traiter l'incontinence urinaire d'effort des hommes et des femmes. Nos avancées technologies permettent d'offrir des dispositifs médicaux qui respectent davantage la physiologie du corps humain. Nos implants sont mis en place grâce à un chirurgie mini-invasive et visent à limiter les risques de récidive précoce ou tardif de la maladie. Les trois prothèses innovantes et la technologie d'Affluent Medical sont en phase sont préclinique ou clinique.

AGS, based in Paris, France, is a group of interrelated companies developing biomedicines based on microalgae extracellular vesicles, or MEVs, as a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, miRNA, proteins, peptides and oligonucleotides for a broad range of human diseases. AGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.

-Artificial Intelligence powered Drug Discovery. -a Biopharma company specialized in medicinal chemistry research of preclinical drug candidates. Ai-biopharma has in-silico solutions of Chemoinformatics, Molecular Modeling, Docking, Data analysis, SAR formatting/interpretation and also an Artificial Intelligence platform for the accelerated drug design towards the selection of new preclinical candidate drugs .

Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the fields of immunomodulation and immunotherapy of cancer focusing on the development of monoclonal antibodies with technologies aiming at Treg depletion in solid tumours. The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi. Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam, has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results. The Company has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors are: Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.

At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to 𝗱𝗶𝘀𝗿𝘂𝗽𝘁 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿, 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀, 𝗮𝗻𝗱 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀. We're developing a breakthrough cell therapy platform with the potential to: • 𝗥𝗲𝗽𝗹𝗮𝗰𝗲 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝘀: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • 𝗘𝘅𝗽𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝗮𝗹𝗹: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • 𝗗𝗿𝗮𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲 𝗰𝗼𝘀𝘁𝘀: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally. 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 Founded in 2022, Allogenica has rapidly emerged as a pioneer in the field. Our innovative approach includes: • 𝗣𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗣𝗿𝗲-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: Enhancing compatibility with patients' immune systems, reducing the risk of rejection. • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗕𝗿𝗼𝗮𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Our platform has the potential to treat a diverse range of diseases, ensuring scalability and reaching more patients in need. • 𝗖𝗼𝘀𝘁-𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲, 𝗥𝗮𝗽𝗶𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Delivering affordable and faster-to-market therapies, to change lives on a global scale, potentially impacting millions.

Alzprotect is a biopharmaceutical company that develops drug candidates, from their discovery to clinical trials, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and tauopathies such as Progressive Supranuclear Palsy (PSP).

ANS Biotech is a preclinical Contract Research Organization (CRO) based in Riom, France, specializing in in vivo pharmacology for pain management. Founded in 2006 by experienced scientists, the company partners with pharmaceutical and biotechnology firms to support their drug discovery and development efforts. The company offers a variety of services, including early screening to evaluate drug candidates, development of predictive in vivo models of pain, and customized research solutions. ANS Biotech also provides consulting services to help clients navigate drug development complexities. A key technology is the ALGOGram™ 2.0 platform, which assesses the efficacy and safety of drug candidates, aiding in decision-making during early-stage development. With a commitment to high-quality and ethical service, ANS Biotech has worked with over 160 clients globally, focusing on advancing new analgesic treatments. The company's core values emphasize engagement, excellence, integrity, and passion in delivering results for its partners.

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. We are growing and hiring! Check our career website: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA on our Welcome To The Jungle page: https://www.welcometothejungle.com/fr/companies/aqemia

Argolight is specialized in integrated fluorescence quality management Pharmaceutical, diagnostics and biotech companies use our tools to make their fluorescence-based measurements more reliable. They reduce maintenance downtime, cost and gain a greater visibility over the state of their systems fleets. Our tools are specially tailored for intensively used systems and environment where quality is important. We invented a patented technology that enables our clients to compare results performed on different systems and monitor data on a large scale. The solution allows system wide diagnosis in 5-15 minutes instead of a day, thus reducing the downtime of the machine, increasing productivity while insuring quality management. As OEM, we provide manufacturers with solution to monitor their fleets enabling cross-systems data mining. Contact us, to see how you can get more from your fluorescence measurements. 

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies.

Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD).

Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug www.atlanthera.com

At Aton, we're building a team of expert companies dedicated to accelerating the progress of tomorrow's therapies. To help deliver the right treatment, to the right patient, at the right time. Aton's Ecosystem – Lifescience platforms united to transform therapies Our platforms are driving a fundamental shift in how medicines are developed. Toward products and services adapted to the patient's biology. Complimentary cutting-edge businesses, with unique technologies and diverse teams of experts. One goal. To accelerate discoveries for the good of patients, medicine, and society. Aton's platforms guide and support life-science businesses to achieve their goals with greater efficiency. Our Strategy We're driven by our ambition to develop tomorrow's therapies. We invest in, guide, support, and develop lifesciences companies with unique technologies. Our strategic investments focus on advancing personalized medicine. We collaborate with the brightest entrepreneurs, to provide flexible and longterm support. To ensure they reach their full potential — to help advance today's and tomorrow's medicines. To transform patient outcomes for good. Many specialists, working as one team, we're constantly moving forward, to take our place at the cutting-edge of medical advancements. We see the future of health. It's safer, targeted and more effective. We understand what it takes to deliver to health and regulatory requirements. Helping make this future a reality.

Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.

BCI Pharma is an innovative bio-pharmaceutical company focused on small molecule drug discovery. We design innovative chemical libraries and our HTS platform can support your owned library synthesis. Founded by : - Dr. Dominique Surleraux who was head of research for a pharmaceutical company (J&J) and two biotech companies (Idenix and Tibotec). - Dr. Elisabeth Picou who had a position in a hospital, treating patients with infectious diseases.

Bcv is a french Medtech company spin-off from the Intelligent Robotic Systems Laboratory (ISIR) at Sorbonne University and the Rothschild Foundation Hospital in Paris. A multidisciplinary team developing innovative technologies for endovascular procedures, for immediate improvement and future applications. Our first focus? STROKE Discover our actuable guidewire with electronically controllable shape-ability designed for the interventional neuroradiology procedures. Objective? Enhance endovascular access & navigation in any anatomy. Our first-ever Shape Memory Alloy actuated system is : - Suitable for minimally invasive interventions, - Unique, a single solution that could replace the package of traditional devices, - Ergonomic, its unique smart handle allows electronic actuation and a controllable torque of the catheter tip robotically to conform to arterial tortuosities, - Compatible and complementary with Robotics and Image Guided Therapy, in a patient-oriented specific design. Objective ? Reach the most complex parts of the human body, providing a game-changer solution for endovascular minimally-invasive procedures. Caution: Investigational device, not yet available for commercial sale, worldwide.

To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

BIOBank is a leader providing high-quality bone allografts to surgeons in orthopaedics, maxillofacial, and dental surgery. Our bone grafts are sourced from living donors in France & processed via our perfected Supercrit® technology, providing key advantages to surgeons and patients: - Total viral-inactivation - Maintainance of biomechanical and structural intergrity of the tissue - Availability in various shapes & forms, allowing easy handling during the surgical procedure - High quality bone integration, improving patient recovery BIOBank assure l’ensemble des activités d’une banque de tissus, de la prise en charge des tissus (recueil) à la délivrance de greffons sécurisés. Ces étapes comprennent, entre autres, la sélection biologique des donneurs puis la transformation proprement dite des greffons osseux.

BIOCORP is a French company specializing in connected devices. Since October 2023, BIOCORP is a 100% Novo Nordisk company. The production plant is located in Issoire and the R&D and operational support teams in Cournon d’Auvergne. Every day, our 100 employees are mobilised around a single objective: to offer professional innovative solutions improving the daily life for patients. We develop innovative connected devices helping in the management of various diseases. As an example, we are offering Mallya, a medical device dedicated to patients living with diabetes, turning any insulin pen into a smart device. Our company is growing quickly but will not lose its start-up spirit! Do you have the taste for challenge and want to join a team focused on innovation, ready to reinvent itself every day? At Biocorp, we work with agility, for quality results and persistently in the aim of innovating. All of this in an environment that constantly seeks to promote well-being at work. Are you looking for a professional environment in which you can evolve, where your job is not a fixed definition of who you are, but the starting point of a career? Come and join us!

BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a master hub protein in the initiation and maintenance of neuropathic pain (Nature Communications 2018). Morevover, Biodol discovered that its FLT3 breakthrough platform will also help fighting the "Opioid Crisis"​ (patented but yet unpublished). Biodol has a series of FLT3 selective small-molecule extracellular antagonists. The Biodol's FLT3 technological Platform is worldwide protected by 5 patents.

bioMérieux develops in vitro products to diagnose infectious diseases, cancer and cardiovascular disease and to detect microorganisms in agri-foods, pharmaceuticals and cosmetics.BioFire COVID-19 test

BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently. The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments. We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery. Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release. BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.

Biopredic International is committed to support Life Science Research by developing and distributing biological tools. We assist both academia and industries in drug development, drug discovery, cosmetic and chemical fields. Biopredic International delivers assays, tissues, cells and reagents including: > High quality hepatocytes (human and animal, fresh or cryopreserved) and other liver-derived products (microsomes, S9 fractions and cytosols) > Skin products (fresh or frozen), including human skin discs and skin sheets (full thickness, dermatomed, stratum corneum), skin cells (keratinocytes, fibroblasts), subcellular fractions… > Blood products, including whole blood, sera, plasma, PBMCs, lymphocytes, monocytes, dendritic cells, CD34… > And other products such as biofluids (bile, gastric & intestinal fluids), non-standard human and animal tissues Applications include: - toxicology - genotoxicity - metabolism - passage - bioanalysis - and tranporter analysis. Biopredic International is also the exclusive worldwide licensor of HepaRG®, the human hepatic stem cell line patented by the French National Instituteof Health and Medical Research. Google+: https://plus.google.com/+BiopredicInternationalSaintGrégoire/posts Twitter: https://twitter.com/Biopredic_Intl To apply for a position at Biopredic International please send your CV and cover letter to recrutement[at]biopredic.com

Bioprojet is a pharmaceutical laboratory committed to science and health. In the last 40 years, we’ve brought forward breakthrough medicines, helping patients struggling with challenging diseases. With passion and integrity, we follow the path set by Jeanne-Marie Lecomte and Jean-Charles Schwartz, founders of Bioprojet. At Bioprojet, we grow to keep honoring our motto : Passion for Research. Research for Patients.

Bioptimus is a developer of a universal AI foundation model designed to drive advancements in scientific research and biotechnological innovations. Their mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine.

Bioréa relies on 10 years of expertise and our innovative & patented technology of closed air-lift bioreactor. Our core businesses are: - Cultivation of different micro-organisms (microalgae, yeast, bacteria) for nutrition & health, cosmetics, pet-food, animal feed and aquaculture. - Tailor-made biomass projects, liquid or powder, ready to use or for extraction. From R&D to production.

BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable. BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR). The BioSourcing disruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation. BioSourcing strongly contributes to sustainable development, in particular in drasticly reducing the carbon footprint. BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry.

Créée en 2005 et basée à Strasbourg en Alsace, la société BIOSYNEX conçoit, fabrique et distribue des Tests de Diagnostic Rapide (TDR). Dans leur version professionnelle, ils offrent une meilleure prise en charge médicale des patients grâce à la rapidité de leur résultat et à leur simplicité d'utilisation. Dans leur version autotest, ils permettent au grand public une autosurveillance de diverses pathologies assurant ainsi une meilleure prévention et accélérant la demande de soins. Leader sur le marché des TDR en France, BIOSYNEX est le seul acteur à maîtriser intégralement sa chaîne de valeur grâce à sa plateforme technologique déclinable sur de nombreuses applications et adaptée à différents types d'utilisateurs tels les laboratoires, les hôpitaux, les médecins et le grand public. Acteur majeur de la santé publique avec 140 collaborateurs et une gamme de 1700 références en France dont notamment le test Exactop du dépistage du HIV, BIOSYNEX a reçu en novembre 2017 les prix de l'Innovation dans la catégorie Biotech & Science de la vie et le prix de la société cotée Euronext au palmarès national du Deloitte In Extenso Technology Fast 50. Plus d'informations sur www.BIOSYNEX.com BIOSYNEX was founded in 2005 and is one of the most significant European manufacturers and provider of rapid membrane tests in the in-vitro diagnostic market. By staying close to our customers and business partners we are aware of the needs and expectations they may have of our products and services. Listening to their voice, together with the help of our Research and Development laboratories in France and our state of the art manufacturing facilities, allows us to identify new applications in rapid testing, develop and launch innovative products and provide high quality services. Our aim is to provide innovative diagnostic tests to help physicians make fast and better medical and therefore lifesaving decisions.

Bio-Xtal is historically a provider of structural biology services. Since twelve years, our know-how in structural biology allowed us to perform projects ranging from domain definition to the structure resolution of protein/ligand or protein/protein interactions by Xray crystallography and NMR. We put an emphasis on monitoring the activity of our targets to ensure the relevance of the structural data we deliver. Our policy is to systematically develop home designed activity assays during our structural biology projects. Mastering eukaryotic and prokaryotic expression systems allows us to supply high quality protein for the needs of your compound screening as well as for structural studies of the selected compound’s complexes, guarantying the coherence of the results obtained on both sides A new key service from of Bio-Xtal is the cytosoluble single chain antibody fragment selection (Cytobody™). These can be raised against any antigen within a very short delay (4 weeks) and are very well expressed in either mammalian or bacteria cells. This allows their expression in Coli for large scale production and expression within mammalian cells for cellular biology applications. The applications of the Cytobodies ranges from the discovery of new druggable sites in multi-domain proteins to immuno-detection, cell imaging, protein purification, and protein stabilisation.

BiPER Therapeutics is developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.

BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness. Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons. BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology. Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. To fund this next phase and secure market approval by 2027, we are opening our capital to those eager to join a unique human and scientific journey. We are supported by prominent investors such as Bpifrance, Ibionext, and Turenne Capital. Now, we aim to raise €35M, with €5M available for participation through the crowdfunding platform Tudigo. Become a BrainEver shareholder 👉 https://tudigo.typeform.com/brainever

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply. Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development. We are currently envisaging clinical collaborations. Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.

Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.

Our R&D center, located in the heart of the Cosmetic Valley in Chartres, focuses on analyzing the compatibility of cosmetic products with the skin. Our microbiology laboratory assists our clients in scientific expertise, marketing communication of claims, and helps R&D scientifically substantiate claims. It stands out for its commitment to innovation, combining industrial and technological expertise to advance knowledge and expertise on the microbiome for cosmetics.

CAPACITÉS is the subsidiary of University of Nantes, dedicated to the development of research. Specialized in engineering of innovative projects, CAPACITÉS exploits the latest scientific discoveries necessary for the performance of its customers. Springboard to differentiate in the ever-changing markets, areas of activity extend to technological and engineering sciences, human and social sciences and health. The activities of CAPACITÉS have advanced expertise on specific and cross-cutting themes. From idea generation to their implementation, CAPACITÉS impulse with its customers a strong value creation process through the development of R&D of high level dedicated to nine economic sectors.

Caranx Medical is a healthcare technology company based in Nice, France, founded by a team of experts including an entrepreneur, a clinician, and a researcher. The company focuses on enhancing access to less invasive medical care through innovative technologies. Its mission is to standardize complex surgical procedures, reduce risks associated with human error, and improve outcomes for patients and healthcare providers. The company specializes in developing intelligent robotic systems to improve surgical precision. One of its key products is the TAVIPILOT, a robotic solution designed for aortic valve procedures. Caranx Medical is also advancing the field with TAVIPILOT Soft, an AI software for real-time guidance during heart valve implantation, which is set for FDA submission in January 2025. The company has achieved significant milestones, including the world's first robotic-assisted heart valve implantation in an animal in April 2024. With a diverse team of over 20 professionals skilled in robotics, software management, and artificial intelligence, Caranx Medical is committed to driving innovation in interventional cardiology and improving patient care worldwide.

Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS). The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs. With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells. Today, our three clinical programs target patients with B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML). We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA). We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases. At Cellectis, we are committed to a cure. Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/ Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) . TALEN® is a registered trademark owned by the Cellectis Group.

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single-cell isolation and bioprinting : Ability to manipulate single-cell has long been a challenge for the scientific community due to their micrometric size and delicate nature. Cellenion has developed and patented CellenONE, a breakthrough single cell isolation and dispensing technology. CellenONE provides outstanding single cell precision, high throughput, and unmatched recovery. Bioprinting is the process of generating spatially-controlled cell patterns using 3D printing technologies. Cellenion will aim toward both miniaturization and automation in order to produce reproducible models of different complexities.

CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans.

Cephagenix is focused on identifying and developing new effective migraine treatments

CERES BRAIN Therapeutics is dedicated to treat cerebral diseases with a first focus on rescuing suffering neurons with creatine through an innovative "creatine-to-brain" concept. The first indications are Creatine Transporter Deficiency syndrome, a disabling condition with no treatment affecting children and Amyotrophic Lateral Sclerosis. The lead compound CBT101 demonstrated efficacy in a preclinical models models as well as a large cerebral and neuronal distribution in primate. The CMC reached noticeable milestones with several GMP batches produced. Other mitochondriopathies are in the Ceres's pipeline. CERES BRAIN Therapeutics has already raised up to 12M€ to move towards the clinical program.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

CILOA’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high-potential bio-drugs. By overcoming undruggable targets, Ciloa supports your projects to create new therapeutic and new preventive solutions. Ciloa customizes in vivo exosomes to contain i) fully native membrane protein complexes (GPCRs, Kinase Receptors, Ion Channels, Viral Antigens, Transporters…) embedded in their membrane and ii) chosen cargo proteins inside their cytosol. Natural properties of exosomes combined with Ciloa in vivo disruptive technology allow to develop: - VIRUS-FREE candidate THERAPEUTIC VECTORS able to deliver specifically chosen cargos to any diseased organ. - ANTIBODIES AGAINST UNDRUGGABLE MEMBRANE PROTEIN COMPLEX TARGETS by unlocking all bottlenecks of the antibody development process. - ADJUVANT & VIRUS-FREE candidate VACCINES, thanks to the combination of perfect antigens with the potent natural adjuvant properties of exosomes. Ciloa works through Licensing and Partnerships.

Clarteis is a French company located in Sophia Antipolis, known for its innovative dermatology medical devices. The company develops and manufactures CE-certified and FDA-approved products, emphasizing quality and innovation. Clarteis holds ISO 13485:2016 certification, ensuring high standards in its production processes. One of its key products is the exciplex®, a portable monochromatic excimer light device designed to treat various localized autoimmune skin conditions, including alopecia areata, vitiligo, psoriasis, atopic dermatitis, and mycosis fungoides. Clarteis has a global presence, with its products approved in over 45 countries, including the USA, Europe, and Japan. The company also offers support and resources for its products through a network of distributors and partners, promoting collaboration in the dermatological field.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

CliniSciences commercialises reagents (antibodies, recombinants, ELISA kits, RNAi, cDNA clones, probes, PCR/qPCR reagents...) to diagnostic and research labs. As very dynamic company, we do our best to be close to our customers'​ needs in terms of high quality reagents that we propose and in terms of service that we provide (search for a particular antibody, technical support, delivery time, etc.) Our principal assets for better serving you : adaptability, flexibility, reactivity and naturally the competence of the technical specialists at your service.

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

Biodesigning the Future of Regenerative Medicine & Skincare

Corteria Pharmaceuticals - FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF WORSENING AND ACUTE DECOMPENSATED HEART FAILURE Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients. We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.

CorWave is a French company developing innovative cardiac assist devices. CorWave's wave membrane pump is a breakthrough technology that differs from today's commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave's membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up studio MD Start and is funded by renowned investors including Bpifrance, Exor Ventures, EIC Fund, Financière Arbevel, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital and Vlerick Group. The company has secured over €80 million in equity and employs over seventy people.

Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company's award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company's other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

CryoTherapeutics is a company that focuses on developing cryotherapy systems for the treatment of heart attacks in Europe and the USA.

CSBio is a leading peptide and peptide synthesizer manufacturing company located in Silicon Valley, California. For over 30 years, CSBio has been producing automated peptide synthesizers, high quality custom peptides, and cGMP peptides for the global pharmaceutical community. Our peptide products and peptide synthesis equipment can be found in peptide production laboratories and pharmaceutical companies worldwide.

Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus for Cure51 is initially to start with 3 types of particularly agressive cancers and will naturally expand to other indications and therapeutic areas to capitalize on its exclusive and unprecedented set of data and discovery pipelines.

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.

CVasThera is a early clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for cardiovascular and bowel pathologies.

CYTEA BIO is a pre-clinical stage biotech company developing therapeutic products by combining genetically unmodified effector cells and engineered targeting ligands. Its patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands for applications in oncology and immunology. CYTEA BIO is the first portfolio company of MedXCell, a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.

CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.

D&A PHARMA is a Specialty Pharma committed to providing effective and innovative treatments to patients suffering from various addictions (alcohol, opiates, cocaine…). In 2017, the treatment of alcohol and cocaine dependences is still an unmet medical need with more than 100 million patients worldwide suffering from their addictions, developing serious attributable diseases and creating significant burden. D&A PHARMA lead product, ALCOVER, is targeting the treatment of alcohol-dependent patients with a Very High Drinking Risk Level (daily alcohol consumption > 60g for women and > 100g for men). Life expectancy in this population is estimated at only 47 to 61 years, underlying the urgency to treat these patients. ALCOVER has shown to be effective and safe in both the detoxification phase and the long-term maintenance of alcohol abstinence with unprecedented efficacy results in this population. ALCOVER is approved in Italy and Austria and registration is ongoing in 10 other EU countries. Two other pharmacotherapies aiming at treating opiate and cocaine addictions respectively are under development with promising results. Our Culture, Values and Company's size foster a fast-paced, dynamic, forward-thinking, friendly and team-working environment. Look at our job opportunities and join us!

DavosPharma is a leading provider of discovery, chemistry, biology, and formulation services. We provide scientific expertise and technical and regulatory support during drug development for academic institutions, emerging biotech, and established multinationals. In an increasingly fragmented marketplace, DavosPharma strives to deliver the best solutions for your specific needs, timelines and budgets. We are unique in the industry because we are paid on deliverables, not ‘best effort'. DavosPharma has a 40 year track record of continuous success. Benefit from our experience and talent.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform's features and data.

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

Receiving blood is receiving life. DIAGAST's goal is to help healthcare professionals transmit life with the help of the best blood group determination technologies. Even though it is not always a matter of life and death, transfusion errors are never acceptable. Over the last 30 years, DIAGAST has developed unparalleled expertise and know-how in the transfusion sector. DIAGAST develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST also ensures the research, manufacturing and marketing of all its products. Moreover, DIAGAST offers a wide range of related services, such as a training center for their automated systems, a hotline and on-site follow-up on automaton calibration. We even make control and measurement tools available over the Internet. DIAGAST is now the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions.

Dianosic ambitions to become a leading company in solving challenges in patient’s adherence to medication. We provide an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases.   Dianosic aims to fight against debilitating chronic diseases that affect millions of people. Our first focus is on chronic allergic rhinitis and chronic rhinosinusitis. Currently, 85% of allergic rhinitis patients are not compliant with their treatment. Furthermore, 20% to 25% of patients do not respond to first-line treatments. These medical challenges significantly impact patient’s quality of life.   We closely collaborate with healthcare professionals, including physicians in otorhinolaryngology (ENT) and neurosurgery. Our multidisciplinary team works hand in hand with them in order to design solutions that change physicians’ experience and offer patients minimally invasive and non-surgical options. Dianosic develops ARIS, a unique platform that benefits from proprietary drug-eluting, long-term resorbable polymer. Our unique concept is meant to deliver patient centric, “insert and forget” solutions, maximizing patient quality of life and addressing physicians’ needs in terms of efficacy, safety, ease of use and patient adherence to treatment.

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France).

D.I.V.A. Expertise est une société de conseil, de stratégie et de développement en recherche scientifique dans les domaines de la Santé, de la Nutrition, de la Cosmétique et de l'Esthétique. Ses objectifs sont de soutenir les industriels dans la structuration, l'organisation et le développement de leur recherche afin d'optimiser ses coûts, délais et résultats. L'accompagnement personnalisé par nos experts dynamise le processus R&D d'un produit en promouvant Créativité, Innovation et Collaboration. Son cœur d'expertise est ciblé sur la biologie du tissu graisseux dit adipeux, reconnu comme organe endocrine avec un rôle fondamental et central sur l'homéostasie générale. Le partage de compétences, de valeurs scientifiques et humaines est à l'origine de la constitution de l'équipe de D.I.V.A. Expertise. A l'interface de quatre mondes Académique, Industriel, Médical et Chirurgical, D.I.V.A. Expertise a créé un réseau regroupant des experts multidisciplinaires et de renommée internationale dont elle assure l'animation et la coordination. D.I.V.A. Expertise (Développement, Innovation, Valorisation, Action en recherche) Ensemble, Embellissons la Recherche Pour plus d'informations, visitez notre site : www.diva-expertise.com Pour nous contacter, écrivez-nous : contact@diva-expertise.com

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

Pionner and leader in crop innovation software, since 1984, managing up to 250K agronomic trials per year. Doriane empowers your agronomy department in its digital transformation. Optimize your data, automate your workflows, and make agile decisions! We support innovation in agronomy—whether in the field, lab, or office—to tackle environmental, economic, and human challenges. We offer digital solutions to collect and enhance data for better decision-making. Our goal is to help agronomy teams adopt practices that are more effective, efficient, open, and resilient. Leverage our extensive experience in project management, technology complexity, cyber-security compliance, and evolving scientific knowledge. We bring our full ambition to every project, working closely with customer teams. Our Customer Success Service is fully engaged throughout the project lifecycle to ensure maximum user adoption. Choosing Doriane means more than just acquiring new software; it's embarking on a digital transformation journey with a partner who supports you at every stage to maximize your benefits. Bloomeo agro-testing software manages the evaluation of varieties, inputs, biosolutions, or practices with a systemic approach, emphasizing the environmental context of field data. Bloomeo BioSolutions evaluates the conditions under which a biosolution performs optimally. Bloomeo Product Development software supports product development activities in agronomy: aligning product design with market segments, managing multi-environment trials, standardizing data collection, and optimizing team collaboration. RnDExperience software supports all stages of the breeding process, from crossing to selection and evaluation. Our motto is “Agronomy driven by data!” and stakeholders worldwide appreciate making informed decisions based on meaningful information. Let's discuss your project: https://www.doriane.com/book-a-demo

Duhn Therapeutics SAS, a clinical-stage company co-founded by Landmark BioVentures AG, and OM Pharma SA, a Swiss based global biopharmaceutical company. We are mission-driven to bring new solutions to cancer patients by reshaping the immunological profile of their tumors. The lead program, DHN198, is a clinical-stage asset for solid cancers associated with or resulting from chronic non-resolved immunosuppressive inflammation. Building upon years of collaboration with translational researchers and clinicians from the University of Bourgogne and the Georges François Leclerc Cancer Treatment Center (CGFL), Duhn Therapeutics is strategically located in Dijon, France, where it plans to conduct its in-house R&D operations in partnership with the Laboratory of Immunology and Cancer Immunotherapy (LIIC). Duhn Therapeutics is a company of the nexus of Landmark BioVentures (www.landmarkbioventures.com)

At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

ELICIT PLANT is an AGtech company and a pioneer in the stimulation of field-grown plants through the use of phytosterols. By reducing plant water stress, our patented technology increases yield in situation of lack of water. Elicit Plant develops and provides new effective prevention products against the stress suffered by plants grown by the intake of exogenous phytosterols in the field. Elicit Plant offers a novel solution for reducing water consumption for the cultivation of targeted plants and helps to fight against water stress. Elicit Plants develops a methodology to collect soil, plant development and climate data to quantify the results obtained under real-life conditions.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

Elkedonia is a pioneering start-up company committed to transforming the treatment of mental health disorders. Our mission is to develop a new generation of antidepressants that are fast-acting, highly effective, and safe. Our breakthrough approach is based on first-in-class neuroplastogens, which promote neuroplasticity without the side effects of psychedelics and ketamine. By eliminating risks of dependence, sedation, or psychotic effects, our innovative treatments empower patients to rediscover the joys of life while significantly reducing the risk of relapse and suicide. At Elkedonia, we believe in a future where mental health treatments enhance well-being without compromise. Join us in this therapeutic revolution. 🧠 Innovating for better mental health.

Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of immunotherapies for the benefit of the patients with high unmet needs.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

🔬 About ENTEROSYS At ENTEROSYS, we are science enthusiasts 🧪 driven by a conviction deeply rooted in medical history: for over two millennia, it has been acknowledged that the key to understanding many diseases lies in our digestive system and its interactions with other organs. Based on this ancient wisdom, we have embraced a modern and holistic approach focused on digestive physiology and the communication between the gut and peripheral organs. Specializing in the preclinical evaluation of compounds with therapeutic potential 💊, we utilize cutting-edge techniques to analyze physiological parameters in real time. Our unique expertise enables the development of proof of concept and precise study of the mechanisms of action of molecules aimed at preventing risk factors or treating diseases, including neurodegenerative 🧠 and metabolic disorders. Key Figures: Over 7️⃣ years of experience in preclinical CRO (Contract Research Organization) services 🔬. Over 7️⃣5️⃣% of clients are satisfied with our services and commission one or more additional studies 🤝. Over 5️⃣0️⃣0️⃣ scientific publications produced by the company's co-founders 📚. Our Services: Customized R&D projects 🗝️ to test therapeutic compounds. Innovative studies to differentiate in competitive markets 🚀. Revolutionary methods to speed up asset development 🛠️. A broad range of Unique Technologies: Accelerate the development of your assets with our revolutionary methods 🛠️. Diverse Testing: We provide a wide range of tests for the dermocosmetic 💄, nutraceutical 🌱, and pharmaceutical industries 🏥. Our Mission: To provide innovative preclinical solutions and advanced preclinical models to enhance and strategically position your molecules 💡. At ENTEROSYS, each client receives personalized support tailored to their specific needs 🎯.

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Roughly 30-50% of NASH patients have CKD through common bidirectional pathways leading to severe renal impairment. Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.

Epigene Labs is creating the intelligence-augmenting solution for precision oncology research and drug development. Designed by cancer scientists for cancer scientists, the company's mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection -- to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and launched in France with the support of prominent European investors. Epigene Labs has partnerships with world-class cancer research institutes and biopharmaceutical companies.

eureKARE seeks to identify, select and nurture European science to create exciting new companies with the potential to disrupt and revolutionize the life sciences industry for the benefit of patients, while delivering shareholder value.eureKABIOME is a Biotech Studio dedicated tothe microbiome. It is driven by the believe that the microbiome is the key to unlocking the understanding and treatment of many diseases. Recent scientific advances and major funding rounds underline its huge potential.eureKASYNBIO is a Biotech Studio dedicated to synthetic biology. Synthetic biology is entering a new era thanks to the emergence of disruptive technologies that will impact many fields including bioproduction, agriculture, data storage and human health.

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe (Saint-Aubin-lès-Elbeuf and Vertolaye in France, Brindisi in Italy, Frankfurt in Germany, Budapest in Hungary and Haverhill in the UK), EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris. OUR VISION Reinventing active ingredient solutions to sustainably meet clients’ and patients’ needs around the world in a sustainable way. OUR MISSION We work passionately every day to develop, manufacture and supply active-ingredient solutions for our healthcare partners around the world. We combine our scientific excellence with industrial expertise and a wide range of technologies to deliver solutions that meet the highest quality, social and environmental requirements - all while ensuring stakeholder satisfaction. OUR FUNDAMENTALS We are driven by the success of our clients and their satisfaction * Reliability * EUROAPI is the leading small molecules API player with an unique European industrial platform and proven track record for reliability. * Quality * EUROAPI provides you with active ingredients that meet the highest pharmaceutical standards. * Premium Client Service * EUROAPI manufactures your success through tailored solutions and a long-term partnership approach that provides peace of mind.

Le groupe Eurobio Scientific est un acteur intégré français du diagnostic in vitro. Aujourd'hui, leader sur le marché français du diagnostic in-vitro, le groupe Eurobio Scientific poursuit son développement en intervenant de la recherche à la commercialisation de produits diagnostiques de spécialités et de produits dans le domaine des sciences de la vie. Le savoir-faire d'Eurobio Scientific repose sur la commercialisation de tests de diagnostic de spécialité auprès des laboratoires d'analyses de biologie médicale hospitaliers et privés. Le groupe est également reconnu en France comme étant le leader du marché des tests HLA pour la transplantation. Eurobio Scientific commercialise également en exclusivité des tests et des solutions automatisées conçus par nos partenaires industriels étrangers (américains, coréens, européens…) dans les domaines des maladies infectieuses, de l'auto-immunité et des contrôles qualité. Une offre de qualité : - Une gamme de réactifs et d'instruments dédiés aux laboratoires des sciences de la vie. - Fabrication de ses produits propriétaires en interne, dans l'unité de production implantée dans les locaux de son siège, dans une salle blanche de plus de 400 m² permettant la fabrication d'unité stérile. Production de qualité, appréciée des clients d'Eurobio. Un portefeuille étendu et diversifié de produits propriétaires dans quatre spécialités : la transplantation, les maladies infectieuses, les sciences du vivant et le cancer.

EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.

Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need.

At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

FineHeartis a French medical device company focused on creatingtechnologies in the cardiovascular field. The FineHeartinvention, anI.C.O.M.S. (Implantable Cardiac Output Management System), is wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility.

Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies. « Patients are central to our approaches » Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. It's going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldn't be a direct result of the surgeon's state of mind. We believe it's possible to create tools that will improve both patient outcome and surgeon experience. We believe it's unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europe's best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. We're all in. We're still hiring.

GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases. At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.

GenoSafe is a CRO providing analytical testing services for the evaluation of quality, safety and efficacy of Gene and Cell therapy candidates including : - GLP biodistribution, shedding and immunogenicity studies ; - QC testing, such as viral titration, safety and potency/efficacy testing ; - GCP bioanalysis of patient samples, including immunogenicity, shedding and gene expression studies. GenoSafe brings more than 15 years of experience in the development, qualification and validation of key analytical methods for product and sample testing.

Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50.

Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway serves clients in 380 academic institutions and 170 life sciences companies, including 17 of the top 20 pharma.

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year. To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs. GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights. GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan: Louis-Marie is a biotech entrepreneur with 15 years of experience in the field of innovative therapies and rare diseases; Claire, specialist of the neuronal cytoskeleton, has sound knowledge of preclinical experimental techniques; Its Scientific & Medical Advisory Board is composed of leading international experts in research and treatment of glioblastoma.

Global Bioenergies substitue des produits d'origine pétrolière par des produits d'origine naturelle. En quête de naturalité sans compromis sur la performance, les acteurs de la cosmétique sont les premiers clients de la Société. Dès 2027, la Société exploitera son procédé innovant dans une usine de grande envergure. A horizon 2030, la Société prévoit de devenir un des leaders de l'immense marché émergent des carburants d'aviation durables afin de lutter contre le réchauffement climatique. Global Bioenergies est cotée sur Euronext Growth à Paris (FR0011052257 – ALGBE). L'Oréal est son premier actionnaire avec 13,5% du capital. Global Bioenergies substitutes products of fossil origin with products of natural origin. In their quest for naturalness without compromising on performance, the cosmetics players are the Company's first customers. By 2027, the Company will be operating its innovative process in a large-scale plant. By 2030, the Company plans to become a leader in the huge emerging market for sustainable aviation fuels, in order to fight against global warming. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 - ALGBE). L'Oréal is its largest shareholder, with a 13.5% stake.

GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation. GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

GOURMEY is France's pioneering cultivated meat company. 🌎 We create sustainable cultivated meat delights for an uncompromising and conscious generation. > Join.gourmey.com

At Guerbet, we build lasting relationships so that we enable people to live better. This is our Purpose. We place human cooperation at the heart of our relationships and actions. We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging. A pioneer since 95 years in the field of contrast media, we are a team of over 2,600 people globally, continuously innovating with 10% of revenue dedicated to Research & Development across four centers in France, Israel and the United States.

HalioDx utilizes a proprietary set of Immune biomarkers, advanced image analysis technologies and a unique know-how to develop, manufacture and commercialize immune-based diagnostics services and products.

Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma. Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma. Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.

HEPHAISTOS-Pharma is a biotechnology company developing next generation immunotherapies against cancer. The company was co-founded in 2018 and has raised significant seed funding for its innovative work in cancer treatment.

Igyxos Biotherapeutics, a French biotechnology company, is dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. To transform infertility treatment and enhance patients’ outcomes, we’re pioneering the first monoclonal antibody (mAb)-based treatment that binds to and enhances the activity of gonadotropins – hormones involved in reproduction – and significantly improves their activity for infertility treatments.

Ikonisys is a cell based diagnostics company, that markets the proprietary Ikoniscope® Digital Microscope, designed to deliver highly accurate and reliable detection of rare cells. Utilizing advanced molecular and immunological markers, Ikoniscope-built applications are extensively used in the US and Europe for the diagnosis of a variety of cancers.

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity. Please visit our webpage to know more about our products and offerings https://iktos.ai/products/

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people's lives by learning from the wisdom of their adaptive immune systems. Adaptive's proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.

Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies). > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors. IMPLANET focuses on spine and knee products. Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation. Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals. IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

INATHERYS is a biotechnology company that specializes in precision drug delivery systems for treating proliferative cancers through innovative ADC technology targeting CD71.

InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. IFB-088 is currently in phase 2 trial to treat ALS. Company History InFlectis BioScience has been founded by Dr. Philippe GUEDAT on August 30, 2013. He discovered IFB-088 (INN: icerguastat) in collaboration with an academic team at the MRC Laboratory of Molecular Biology (LMB) in Cambridge UK. Dr Philippe GUEDAT was awarded at the 2013 and 2014 National Competition of Business Startups using Innovative Technologies by the Ministry of Research in France. - 2013: Prize of Emergence section: €50k https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.annee_de_concours=2013&refine.region=Pays+de+la+Loire - 2014: Prize of Creation-Development section: €300k https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.region=Pays+de+la+Loire&refine.annee_de_concours=2014

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Pioneers in the biology of Natural Killer cell, Innate Pharma has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

Créé en 1964, l’Institut national de la santé et de la recherche médicale (Inserm) est un établissement public à caractère scientifique et technologique, placé sous la double tutelle du Ministère de l’Enseignement supérieur et de la recherche et du ministère de la Santé. Ses chercheurs ont pour vocation l’étude de toutes les maladies, des plus fréquentes aux plus rares, à travers leurs travaux de recherches biologiques, médicales et en santé des populations. L’Inserm, chercheur en santé depuis 1964 Avec un budget 2013 de 927 M€, l’Inserm soutient près de 300 laboratoires répartis sur le territoire français. L’ensemble de ses 1200 équipes regroupe près de 15 000 chercheurs, ingénieurs, techniciens, gestionnaires, hospitalo-universitaires, post-doctorants…Il est actuellement dirigé par Yves Levy. L’Inserm est membre de l’Alliance nationale pour les sciences de la vie et de la santé, fondée en avril 2009 avec le CNRS, le CEA, l’Inra, l’Inria, l’IRD, l’Institut Pasteur, la Conférence des Présidents d’Université (CPU) et la Conférence des directeurs généraux de centres hospitaliers régionaux et universitaires. Cette alliance s’inscrit dans la politique de réforme du système de recherche visant à mieux coordonner le rôle des différents acteurs et à renforcer la position de la recherche française dans ce secteur par une programmation concertée. L’Inserm célèbre ses 50 ans en 2014.

Construit au cœur de l'Hôpital national des 15-20, l’Institut de la Vision est l’un des plus importants centres de recherche intégrée sur les maladies de la vision en Europe. Conçu comme un lieu de rassemblement et d’échanges, il réunit sur un même site la recherche fondamentale, clinique et industrielle, favorisant ainsi le partage des concepts et des techniques, la rencontre de compétences et d’expertises complémentaires et l’émergence de nouvelles pistes de recherche. Chercheurs, médecins et industriels y travaillent de concert pour découvrir et valider ensemble de nouvelles thérapeutiques, des solutions préventives, ainsi que des technologies compensatrices des atteintes visuelles.

Situé à Paris au cœur du plus grand centre hospitalier européen, l'hôpital de la Pitié-Salpêtrière, l’Institut de Myologie est né en 1996 sous l’impulsion d’une association de malades et parents de malades, l’AFM-Téléthon. Son objectif : favoriser l’existence, la reconnaissance et l’essor de la Myologie, science et médecine du Muscle, en tant que discipline à part entière. Qu’il soit sain, malade, accidenté, sportif, vieillissant… le muscle, dont dépend notre activité et nos fonctions vitales, est devenu un véritable modèle d’innovation pour la recherche scientifique et médicale et un enjeu de santé publique. L’Institut de Myologie coordonne, autour du malade, la prise en charge médicale, la recherche fondamentale, la recherche appliquée, la recherche clinique et l’enseignement. C’est un centre de référence international qui participe à de nombreux essais et études cliniques concernant principalement les maladies neuromusculaires mais également les lésions musculaires liées au sport de haut niveau ou au vieillissement. Depuis 2005, l’Institut de Myologie est une association régie par la loi du 1er juillet 1901 dont les membres fondateurs sont l’AFM-Téléthon et Généthon. L’Association Institut de Myologie a pour mission de faciliter la coordination des activités du site, en partenariat avec cinq tutelles publiques : AP-HP, CEA, Inserm, Sorbonne Université (ex-Université Pierre et Marie Curie) et CNRS.

The Institut Pasteur, a non-profit foundation with recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research with a network of 33 members worldwide. In the pursuit of its mission to tackle diseases in France and throughout the world, the Institut Pasteur operates in four main areas: research, public health, training, and development of research applications. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology, with research focusing on the biology of living systems. Among its areas of investigation are emerging infectious diseases, antimicrobial resistance, certain cancers and brain connectivity diseases. The Institut Pasteur's outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging, computational biology and artificial intelligence. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS. www.pasteur.fr/en

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

Invectys, Inc. is a privately owned clinical-stage company, headquartered in Houston, Texas, which is developing a new generation of First-in-Class products for cancer patients. Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is directing the clinical development of the Company’s lead HLA-G product. Since 2010, Invectys has raised over $60 million in private funds to develop its two innovative platforms of immunotherapy products which target “universal” tumor antigens.

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

iPSirius SAS, [pronounced ip-Sirius], is a French headquartered immuno-oncology firm, seeking to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.

Created in 2005 through a collaboration between Inserm – Institut National Health and Medical Research – and AFM-Telethon – French Association against Myopathies – I-Stem is the largest French laboratory research and development dedicated to human pluripotent stem cells, embryonic origin or obtained by reprogramming gene. I-Stem is part of the Biotherapy Institute for Rare Diseases, which includes so far the four centers of research and development funded directly by the AFM Telethon. The specific vocation of I-Stem is to explore all the therapeutic potential of human pluripotent stem cells for applications in patients affected by rare diseases of genetic origin. In this context, our teams are developing two major areas of research. The first one is cell therapy, which aims to replace lost or diseased cells to other cells with the same characteristics, produced in the laboratory from pluripotent stem cells. The second area is pharmacology based on automated screening of large libraries of compounds with therapeutic potential, following modeling of molecular mechanisms associated with diseases, as revealed by the study of pluripotent stem cells from affected donors. I-Stem teams are currently working on a dozen genetic diseases that affect different organs. The Institute also hosts every year many researchers interested in other diseases and provides training and technology support.

Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways. Our mission is to develop medicines that will transform the lives of people fighting cancer. For that purpose, we leverage our deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. This mechanism, defined as “non-oncogene addiction” (NOA), offers potential novel, safer and more effective therapeutic strategies. Jalon Therapeutics is rooted in pioneering fundamental research and clinical investigations from INSERM laboratories and Saint-Louis Hospital in Paris. Jalon Therapeutics was cofounded in 2021 by Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jérôme Tiollier, Jean-Christophe Rain and Philippe Salphati. Among the proteins involved in non-oncogene addiction, the scaffold protein AAC-11 (Anti-Apoptosis Clone-11) is a cornerstone component of the signaling networks essential for cancer cell survival, adaptation to stress, resistance to therapies, immune evasion and metastatic potential. Derived from AAC-11, JRT39 is the first-in-class lead candidate developed for the treatment of hard-to-treat cancers. JRT39 properties combine the broad tissue distribution and cell permeability of small molecules with the excellent specificity and target-engagement potency of antibodies, together with unique modes of action. As such, JRT39 stands as breakthrough discovery to treat advanced and refractory cancers, alone or in combination with other treatment modalities. Furthermore, Jalon Therapeutics is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer.

Surgical equipment for different indications in ophthalmology and anterior segment conditions, innovative technology. Ultra-fast Femto Laser for #cataractsurgery, the only machine capable of performing a real #photoemulsification and removal of cataracted lens only with an Irrigation/aspiration cannula. Created in 2015 by @Fabrice Romano and 6 other co-founders, Keranova is the first company in the world able to bring to surgeons a new method for extracting the cataracted lens, by removing thousands of thin particles created with the ultra-fast laser. No more need for the phacoemulsification machine, just an irrigation/aspiration.

Kiji Therapeutic, Incorporated in France and Spain in 2023, develops transformative off-the-shelf engineered cell therapies for life-threatening diseases. Kiji-TX has a platform to gene engineer iPSC derived MSC cells for a targeted and optimized therapeutic benefit. The first asset is engineered with IL10/CXCR4 and targets several autoimmune diseases.

KINNOV was created as a spin off from Greenpharma and Key-Obs, both located in Orléans, 100 km south of Paris France. Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people. KT-110 is the first project based on this new strategy to positively complete a phase 2 trial. KT-110 proof of concept clinical trial on alcohol addiction has started in nov 2019, results were available in January 2022. They were positive and very high risk level population is likely to be targeted for phase 3 study.

KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence. The team at KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians new advancements in imaging and a greater field of view, a must-have in active surveillance and targeted treatment. Based in Grenoble and Princeton, KOELIS technology has been featured in more than 50 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. With most of its products indicated for serious and rare diseases, LFB is a major player in this area. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 5th worldwide and is also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies. With a sustained investment in research and development, the LFB Group bases its strategy on its international deployment and the design of innovative therapies.

Limagrain is an agricultural biotechnology company that specializes in plant genetics, seed production, and crop improvement.

We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

Lumibird Medical is the medical division of the Lumibird Group, an expert in fiber lasers, solid lasers, laser diodes, and medical equipment. Formed from the 2020 merger of three entities – Quantel Medical, Ellex and Optotek – specializing in diagnostic and treatment devices for ophthalmology and other medical fields, our company is recognized for its commitment to innovation and stands out as a world leader in ophthalmic equipment. Our mission is to improve the comfort of patients worldwide by optimizing the standard of care with innovative diagnostic and treatment solutions dedicated to the medical sector. More information in our website!

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities.

May Health is a healthcare company that is developing a modern approach to PCOS.

MB Therapeutics is a pharmaceutical company that offer patient centric solutions to Develop and produce personalized medicines. MB Therapeutics solution is powered by 3D printing, allowing dosage, shape and API customization in GMP environement

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

Better Medicine for All MedinCell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. #BetterMedicineForAll #ImpactHealth #GlobalHealth #ControlledRelease #CreativeThinking #InnovationForward #Science

Meletios Therapeutics’ aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers. One of our first drug candidate has confirmed its broad-spectrum potential in in vitro and in vivo models on the coronavirus family and influenza H1N1, demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to meet regulatory requirements and enter clinical phase II. Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will expand our range of antiviral molecules on different RNA viruses. Meletios Therapeutics’ goal is to become a global leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.

MElkin pharmaceuticals is a biopharmaceutical company identifying and developing innovative new treatments for cancer and brain diseases that are associated with aberrant activation of the MAPKinase/ERK signaling pathway. Founded in 2015, the company is currently engaged in the preclinical development of the PepFos lead compound for cancer treatment.

At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health.

Following several months of strategic review and heavy financial restructuring, Innavirvax is reborn as Minka Therapeutics with a new sense of purpose and stronger ambitions. With positive phase II data in hands for its HIV vaccine, the company has demonstrated the potential value of its 3S/p44L technology platform. The expertise gained in NK cells involvement in HIV disease will be more specifically leveraged to develop new therapeutics in key commercial indications in infectious diseases and in oncology. Minka Therapeutics intends to strengthen its core technology base beyond vaccines and will be announcing key strategic collaborations with leading academic institutions in the coming months.

Mnemo Therapeutics is a biotechnology company focused on discovering and developing immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a global team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine. Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes. Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer. By viewing the human body through the lens of physics a new realm of possibilities has emerged.

Nantes Université is a Higher Education institution that offers academic programs and conducts research.

The first plant-microbiome systems bioengineered to purify indoor air.

Neovacs is a French biotechnology company that develops products and invests in innovative companies in the biotech and life sciences sectors.

NETRI is a technology enabling company that provides human cell based smart assays for high throughput preclinical data acquisition for the neurological Pharma & Cosmetics industries. We provide organs-on-chip solutions & interoperable in vitro models designed to deeply accelerate drug discovery and preclinical trials by mimicking in vivo neural connectivity.

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group. Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

NEUROFIT, founded in 1996, is a pre-clinical CRO (Contract Research Organization) based in France and offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes and pain. Neurofit works for major pharmaceutical and Biotech companies in Europe and the USA. Neurofit's core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune / inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit routinely performs, as part of a study, collection of blood, serum plasma, cerebrospinal fluid as well as dissection of brain microstructures from compound-treated animals to provide customers with useful samples for their pharmacokinetic, biochemistry and immunochemistry analyses.

Say yes to what's next! NextPharma, your CDMO partner for pharmaceutical development and manufacturing with fast, flexible and personalised solutions for worldwide markets. We are a leading European contract manufacturer in the pharmaceutical, nutraceutical, biotech and healthcare industries. For us, the most important step is always the next. Welcome to NextPharma! Because speed drives us, fills our working world with dynamism and allows us to grow. Our best recipe for joint success: space for passion. Because we are sure: Where excellent service inspires, passion is the best medicine. Our 2,300 European employees are located in our centres of excellence in Berlin, Bielefeld, Goettingen and Waltrop (Germany), Limay and Ploermel (France), Tampere (Finland), Edinburgh (UK) and Asker (Norway). NextPharma develops and produces a broad range of pharmaceutical dosage forms: • Solids (tablets, hard and soft capsules, powders, controlled-release pellets) • Non-sterile liquids (emulsions, suspensions, syrups, solutions) • Sterile liquids (ophthalmic and otic solutions and emulsions) • Semi-solids (creams, gels, ointments, suppositories) Special containment areas are available for: • Hormones (solid and semi-solid) • Narcotics (controlled substances) • Penicillin and Cephalosporin beta lactam antibiotics (solids and dry syrups) • Highly-potent compounds (soft gel and liquid-filled hard capsules) • Clinical trials services Career opportunities: Passion meets prospects! Joining NextPharma means taking the next step. A strong step forward. Because you will be adding prospects to your passion. With vision. Whether you are a school-leaver, an entry-level candidate, a specialist or an executive: the pharmaceutical, nutraceutical, biotech and healthcare industries are full of challenges and future potential. And it’s a future that we at NextPharma want to shape. Together with you! #speed #passion #service

NFL BIOSCIENCES clinically develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. It is delivered via two simple subcutaneous injections, administered one week apart, making patient compliance a breeze. There exists vast anecdotal evidence, from more than 10,000 smokers treated off-label in France with a predecessor product developed by the Pasteur Institute, that NFL-101 is safe and efficacious for total smoking cessation at twelve months. A Phase 1 clinical trial that reported data in 2017 confirmed safety and efficacy in smokers willing and trying to quit, in terms of total cessation at twelve months as well as reduction without compensatory over-smoking.

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

At Novacyt, we pride ourselves on concentrating our expertise on specific market needs. Offering a comprehensive and developing portfolio of quality products, backed by proven supply and delivery services, to ensure the highest possible standards of customer service around the world. Our passion is for customer-centric solutions that advance the science behind diagnostics. This fuels our drive to deliver products that save lives and help in the fight against infectious disease. We offer an increasing portfolio of in-vitro diagnostic tests, utilising molecular and protein detection technologies – supporting healthcare and disease prevention across the globe in the clinical and life science sectors. Deep strengths in product development, commercialisation, contract design, and manufacturing ensure quality products and robust supply. Our Group has specialist experience and expertise throughout our business units: Primerdesign, Microgen Bioproducts, IT-IS international, and Lab21 Healthcare – creating solutions for the diagnostics industry, supplying an extensive range of high-quality assays and reagents worldwide.

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Novaptech develops aptamer-based tools in the frame of technology transfer and innovation projects. Novaptech’s expertise is focused on the identification and the characterization of aptamers for biotechnological development of analytical and diagnostic aptamer projects. Novaptech develops collaborative projects or service agreements with academic laboratories and R&D department of companies. Novaptech works in close association with Dr. Toulmé ’s team, an academic laboratory (Inserm U1212, Bordeaux) which has more than 26 years of experience in aptamer selection.

Novian Health is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. Novian Health has developed Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novian Health has received a CE Mark for focal destruction of malignant and benign breast tumors, the first thermal ablation device to be approved for breast cancer. Novian Health’s technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy. Novilase offers significant advantages over surgery including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requires local anesthesia. Novian will conduct a multicenter pivotal trial to evaluate Novilase® laser therapy as a treatment for early-stage breast cancer. U.S. market clearance for the focal destruction of malignant tumors will be sought. Novian will begin commercialization in Europe. Novian Health has received U.S. FDA 510(k) clearance for the treatment of fibroadenomas, or benign breast tumors, and ablation of soft tissue. A registry has been initiated to collect additional information on benign breast tumors treated at centers around the U.S. www.novianhealth.com www.novilase.com

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers. Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic

AI in the service of precision medicine. We don't perform miracles, just create the tools that enable them. At Okeiro, we develop medical AI solutions that transform the monitoring of transplant patients and those with chronic conditions. Our predictive algorithms, scientifically validated digital biomarkers, convert complex medical data into information directly usable by healthcare teams. This technology allows us to: - Detect early signals of complications or graft rejection - Personalize each treatment for truly proactive care - Intervene before critical symptoms appear Our goal is clear: to tangibly improve patients' lives by equipping healthcare professionals with innovative tools that make a daily difference. In close collaboration with healthcare professionals and pharmaceutical companies, we accelerate the clinical validation of therapeutic innovations to make new treatments more quickly accessible to the patients who need them!

We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission' is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.

Oncovita is a preclinical stage biotech company pioneering the development of oncolytic viruses to address unmet medical need. Led by a world-class management, Oncovita is focused on developing innovative medications and vaccines, particularly anti-cancer therapies, to save lives.

One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences.

OneOne's mission is to support farmers in reducing their dependency on problematic agrochemicals. Our platform technology allows for the discovery and delivery of optimized microbes capable of enhancing crop nutrition, health, and growth, along with soil vitality.

Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North America and Europe.

OPIA Technologies is a company dedicated to the development of medical devices with a specialization in ophthalmology but also provides services for medical devices compagnies. One of the main goals is to provide innovative and reliable devices to improve the diagnosis and care of patients with ocular diseases. OPIA is building a complete portfolio of medical devices for sampling ocular surface components (conjunctiva: EYEPRIM , tear film: TEARPRIM) and for non-invasive ocular drug delivery (IONTOFORVET), based on proprietary patents. Activities encompass the whole life cycles of the devices. The team of Opia design, manufacture and warrants the regulatory and quality conformity of its medical devices. Opia benefits from a privileged relationship with JB TECNICS (www.groupejbt.com), a worldwide group specialized in tool manufacturing and clean room molding for the medical industry. OPIA meets the highest level of quality requirements with a certified ISO 13485 quality management system (QMS). OPIA Technologies is also part of the company alliance JBT HUB UP (www.jbt-hubup.com) which offers a global solution for the development of complex medical devices, from inception to commercialization. The services provided by Opia Technologies for medical device companies concerns the following fields: - Project management - R&D - Proof of concept - Regulatory affairs - CE-marking and - Intellectual property/patents - Marketing strategy www.eyeprim.com www.iontoforvet.com

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018). It is currently in phase 2 clinical trial in NSCLC. The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies. The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.

Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.

‘OT4B was created in 2017, at the initiative of the French Prader-Willi community, to support and continue the academic research work of the team led by Professor Maithé Tauber from the National Reference Centre for Prader-Willi Syndrome at the Toulouse University Hospital*, and ongoing in France since 2007. In partnership with the Toulouse University Hospital, our objective is to develop oxytocin as the first treatment for patients with Prader-Willi syndrome and to make it available as soon as possible to the widest number of patients in order to improve the daily life and future of both patients and their families.’

OXELTIS is an independent medchem oriented service company managed by former researchers from Idenix Pharmaceuticals and located in Montpellier - France. Oxeltis is a company that delivers integrated solutions for managing and executing medicinal and fine organic chemistry projects. We run FTE programs (hit to lead optimization) with an expertise in some specialty chemistry such as macrocycles (pseudopeptides), mono & poly/oligosaccharides (sugar phosphates, iminosugars, saccharidic antigens…) nucleos(t)ides (modified nucleosides, phosphoramidites…), short peptides, linkers and PROTACs (Ligands E3 CRBN ligase library ) applied to discovery programs in oncology, antivirals and antibiotics mainly. OXELTIS client portfolio includes 40+ European and US companies from biotech to top 10 pharmaceutical companies. With its team of experienced medchem chemists, OXELTIS is proactive in providing rapid, high quality and competitive work. Specific expertise: - Contract research in medicinal chemistry, FTE programs for hit to lead optimization in different fields including antivirals, anticancer and antibiotics. - Fee-for-service custom synthesis expertise in heterocycles (in various fields), modified sugars (sugar phosphates, iminosugars, unnatural sugars…monosaccharides and oligosaccharides...), nucleoside/nucleotide (sugar and base-modified nucleosides, phosphoramidites…), macrocycles (e.g. antiviral antiproteases) . https://oxeltis.com/ https://twitter.com/Oxeltis_CRO

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection.The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides.

Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimer’s disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de LAVENNE, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr. Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Perha Pharma focuses its research & development on two main programs: - Correction of cognitive deficits associated with Down syndrome: Trisomy 21 and Alzheimer's disease share a common therapeutic target involved in cognitive disorders, the DYRK1A protein kinase. The pharmacological inhibitors of this kinase optimized by Perha Pharma are derived from Leucettamine B, extracted from the Leucetta microraphis marine sponge. These molecules correct cognitive impairments observed in three mouse models of DS and three rodent models of AD. Leucettinib 21, our preclinical drug candidate, has been selected among over 500 synthesized Leucettinibs following a stringent multi-parameter go / no go decision tree. Perha Pharma is now preparing for regulatory preclinical studies. -Prevention of hearing loss induced by ototoxic drugs or noise: Perha Pharma-optimized molecules prevent hair cell apoptosis of the inner ear in cell models exposed to cisplatin. Perha Pharma is working at a proof-of-concept using rodents exposed to cisplatin or acoustic trauma.

Pharmaleads’ mission is to provide precision medicine to relieve the suffering associated with acute and chronic pain. Through the development of our proprietary Dual ENKephalinase Inhibitors (DENKI®) it is our aim to provide both efficacious and safe non-opiate pain therapeutics.

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : 💊 A pharmaceutical group with a strong positioning : medical and natural 🥈 The second largest dermo-cosmetics laboratory in the world 🥈 The second largest private French pharmaceutical group 🥇 The market leader in France for products sold over the counter in pharmacies. Our portfolio includes several medical franchises and international brands including ; Pharmaceutical Care Pierre Fabre Oncologie Pierre Fabre Dermatologie Naturactive Eau Thermale Avène Klorane Ducray René Furterer A-Derma Pierre Fabre Oral Care Glytone (US) Darrow (Brasil) Established in the Occitanie region since its creation, we manufacture over 95% of our products in France. We keep innovating passionately with our teams in 2 innovation centers in Brasil and Japan as well as in 6 R&D centers in France. Thanks to our 9,600 employees in 44 subsidiaries and our distribution activities in 120 countries, our group generated €2.7 billion in revenues in 2022, 69% of which is from international business. Pierre Fabre Group has a unique company structure. 86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan. In 2020, the independent organization ECOCERT Environment awarded Pierre Fabre's CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard.

Pili, carbon conscious color company Pili is the leader in bio-based colorants and pigments. Its unique fermentation and sustainable chemistry processes, enable the production of high-performance, and low-carbon colors. Its technology aims at decarbonizing the color industry by drastically reducing the use of chemicals and fossil resources, particularly oil. Its products are designed for the textile, inks, paints & coatings and plastics sectors. Founded in 2015, Pili operates from 3 different sites: Toulouse White Biotechnology (TWB), Paris and the Roches-Roussillon industrial platform in Isère. With around 40 employees to date, the company has invested over €35 million since its launch to industrialize its innovative processes.

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences. PK MED was created around a small team of passionate and experienced experts in pharmaceutical and medical sciences, drug delivery and biomaterials design. PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Our expertise spans across critical healthcare domains, focusing on drug delivery systems for rheumatology and enhancing cell-homing techniques to improve bone marrow transplantation outcomes. The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis and Hemoglobinopathies.

Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services for viral and non-viral delivery. Custom plasmid vector design and plasmid and protein manufacturing was integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Prestwick Chemical is a French provider of smart libraries. For almost 20 years, the company, founded by Prof. Camille-Georges Wermuth, has provided medicinal chemistry services and screening libraries to accelerate small molecules drug discovery. Prestwick has a large portfolio of smart Libraries designed to ensure maximal chemical diversity, possibly to access new IP while remaining within reach of both low and high throughput screening processes. They are constantly updated and improved. Our clients have reported high quality hit generation rate. The Prestwick Chemical Library®, a unique collection of 1520 small molecules (95% of approved off-patent drugs) is our flagship and is mentioned in 400+ publications worldwide. New innovative collections continuously feed our portfolio: Our Prestwick Drug-Fragment library has been designed to optimize the chance of success in Hit finding using Fragment-based Drug Discovery. Prestwick Chemical became a brand of Greenpharma in 2021.

Priothera - We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

About Promise Proteomics Promise proteomics is an expert in the bioproduction of Stable Isotope Labelled monoclonal antibodies and proteins, considered as internal standards for absolute quantification by mass spectrometry. Promise Proteomics offers products and services in two main areas : • Stable isotope labelled and unlabelled protein and monoclonal antibodies. We offer a range of products and services for customized bioproduction. • Innovative kits dedicated to monoclonal antibody quantification by mass spectrometry. mAbXmise kits are ready-to-use sample preparation kits, including our stable-labelled mAbs as internal standards and all the required reagents and consumables. mAbXmise targets 20 t-mAbs on the market, used in various therapeutic areas.

ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides. Our custom services ensure a unique and tailored process to our clients revolving around four areas : Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells Monoclonal antibody production and Polyclonal antibody production Gene synthesis, sub-cloning and mutagenesis Peptide synthesis, purification and conjugation ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.

Founded in 1981 and based in Paris (France), Prothia has established itself in the world of medical devices and equipment and has acquired a particular understanding of cardiovascular, perinatal and rehabilitation applications. Our existing products and those in development create major global growth opportunities. We recently created our American structure in Massachusetts (Worcester). We look forward to meeting candidates interested in our field and our way of working. Prothia supports clinicians to help them achieve their therapeutic and diagnostic objectives. Listening attentively defines us. We strive to be helpful and do what we do well.

PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.

Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

Qynapse is a neuroimaging technology company founded in 2015, originating from the CATI consortium of neuroimaging research laboratories. Based in France, with offices in the U.S. and Canada, Qynapse is dedicated to enhancing the diagnosis and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. The company focuses on improving accuracy and reliability in clinical and research environments through AI-driven solutions. Qynapse offers proprietary AI-powered tools for analyzing neuroimaging data, such as MRI and PET scans. Its key product, QyScore®, features an automated platform with 20 algorithms and over 200 measures for assessing neurodegeneration and neuroinflammation. The company also provides clinical trial solutions that significantly reduce image-reading variability, enhancing trial efficiency, and normative datasets that deliver precise imaging metrics for tracking disease progression. Qynapse serves pharmaceutical and biotech companies, healthcare providers, and researchers, aiming to improve patient outcomes and accelerate drug development timelines.

Build the first Radiological Foundation Model Bring the radiological image to GPT Share the world's top medical expertise through AI Bring the best specialist to every patient/researcher/company

Rime Bioinformatics is a research and development biotechnology company with a focus on bioinformatics. As studying the genome of phages is key to detect lysogeny, toxicity, or antibiotic resistance genes, bioinformatics plays acentral role in the R&D process that leads a phage to market. Rime Bioinformatics’ mission is to make high-performance bioinformatics accessible, thanks to their solutions based on expert bacteria and phage genome annotations.Their technologies yields a 5x better understanding of phages genomes than traditional methods. This allows higher throughput screening of candidate phages and provides solid evidence to support phage-based products' proofs ofconcepts. Rime Bioinformatics is focused on delivering state of the art analysis and high quality results, summarized in clear and comprehensive reports.

Established in 2015 and based in France, SafeHeal™ is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal's premier device, Colovac, was invented by French surgeon Charam Khosrovani to eliminate the need for diverting ostomies in patients undergoing colectomy.

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Scipio bioscience had to cease its operations on 18/09/2024. At Scipio bioscience we were passionate about empowering every researcher to discover the molecular mechanisms of life for better health and a sustainable world. Enabling deeper insights into disease understanding, Scipio wanted to boost the access to and increases the pace of discoveries with its Asteria benchtop kit for easy scRNA-seq sample preparation and its Cytonaut intuitive cloud-based data analysis software for biologists and bioinformaticians alike. Scipio provided all researchers with empowered autonomy to embrace the next step in single-cell, working with unaltered transcriptomic data for the highest-quality results and true biological information. Scipio bioscience was housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.

Surgery-assisting machines

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

Founded in 2017, SeqOne Genomics headquartered in Montpellier, France, is a fast-growing deep-tech company focused on turning genomic data into medically actionable insights in oncology, rare and inherited diseases. SeqOne clinical genomic analysis platform, powered by explainable AI, provides genomic labs and healthcare professionals with best-in-class accuracy, usability, and automation seamlessly across lab technologies. By streamlining complex multi-omics analysis workflows, we pave the way for a new era of personalized healthcare at scale, where genetic testing becomes as routine as traditional blood work, radically enhancing health outcomes for all. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

Smart Immune is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, enabling next-generation allogeneic T-cell therapies for all. The company is a spin-off from the Imagine Institute of Genetic Diseases, and was founded in 2017 by Karine Rossignol, PharmD-HEC, Marina Cavazzana, MD-PhD and Isabelle André, PhD to transform outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has clinical partnerships with leading institutions in the US and Europe. The ProTcell platform, already in Phase I/II clinical trials, enables the accelerated recovery of a complete immune repertoire in patients fighting cancer and infection. The ProTcell platform introduces potent, allogeneic T-cell progenitors which are then differentiated by the thymus into fully functional T-cells, to ultimately develop an ‘off the shelf’ T-cell medicine. The company is headquartered in Paris, France, at Paris Biotech Santé.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management. For more information, please visit: www.sofinnovapartners.com

SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.

SpikImm was founded in 2021 by Truffle Capital and the Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID-19 infection. SPK001, SpikImm’s lead candidate, originally developed in the laboratory of Humoral Immunology (Institut Pasteur) headed by Dr Hugo MOUQUET, has demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and all pathogenic variants (including Delta and Omicron), as well as a therapeutic efficacy in vivo in mouse and hamster models. SPK001 is developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of COVID-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination. SpikImm expects to start clinical trials mid-2022.

Making Spine Surgery Safer SpineGuard is a French innovative medical company dedicated to the deployment and adoption of DSG® (Dynamic Surgical Guidance), powerful radiation-free real time sensing technology platform that spans a broad spectrum of skeletal applications from bone drilling instruments to automated placement of bone implants. Uniquely positioned to change the game in orthopedic robotic surgery. Devices, built with the DSG technology, give real-time audio and visual feedback to the surgeons to secure and streamline skeletal implant placement for the benefit of patients, surgeons, operating room staff and healthcare providers. The PediGuard probes are the only devices with built-in DSG capability to improve the accuracy of pedicle screw placement. The PediGuard probes are handheld tools used by spine surgeons to perform pilot holes in the vertebrae before pedicle screw placement. An electrical conductivity measurement sensor, located at the tip of the drilling instruments, alerts the surgeon in real time and without using X-Ray imaging, about changes in conductivity that occur at the transition between cancellous bone, cortical bone and soft tissues/ blood. These devices are used in surgeries for all kind of patients, from pediatric in deformity corrections to adult in degenerative diseases requiring internal fixation. These medical devices have assisted spine surgeons in accurately placing pedicle screws in over 90,000 spinal procedures around the world. With mounting clinical evidence (24 major Peer-Reviewed publications) confirming its efficacy, PediGuard devices are becoming a compelling answer to the clinical needs associated with safe and accurate pedicle screw placement.

Spotlight Medical is a precision medicine company striving to free all patients from cancer through a better understanding of each patient’s unique disease. We develop advanced AI tests that enhance treatment selection by leveraging decades of patient data. This ensures personalized and effective care for each individual, significantly improving patient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests that address critical unmet clinical needs, opening a new era in cancer care. Founded in 2024, Spotlight Medical is backed by Institut Curie and Gustave Roussy, and has raised more than 6 million Euros to implement its first AI-driven test in clinical routine set to be announced soon.

Created in 1945 as a pharmaceutical company, Diagnostica Stago is now a world leader in the In-Vitro Diagnostics industry. Global, privately-owned and independent, Stago is fully dedicated to the exploration of Thrombosis and Haemostasis. Day in and day out, Stago is committed to enhancing the quality of healthcare by offering laboratories advanced testing systems and superior services, the fruit of our expertise and know-how in Haemostasis (reagents, instruments and disposables). Distributed in over 110 countries through a network of subsidiaries and exclusive distributors, we are in a position to guarantee our customers superior service and a product portfolio meeting the demands of global healthcare systems. Today, 90% of our production, developed and made in France, is exported. Specialising in the field of coagulation for over 60 years, Stago has acquired solid industrial experience (R&D, standardisation and production) in the field of In Vitro Diagnostics and lasting recognition from the scientific community. The field of biomedical science is constantly evolving and expanding; new discoveries are moving medicine increasingly towards individual treatments that require diagnostic markers and ever more precise exploratory tools. These are our challenges of tomorrow. Stago, relying on strong human and technological potential, will still have much to contribute in the years to come.

Stallergenes Greer is a global biopharmaceutical company specialising in the diagnosis and treatment of respiratory, food allergies and venoms through the research, development and commercialisation of allergen immunotherapy products and services. Our purpose is to enable precision medicine to improve life for people with allergies. With nearly 1,100 employees worldwide, a presence in 44 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy. Link to our privacy policy: https://www.stallergenesgreer.com/personal-data-protection-policy

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world's first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

Stimunity is a preclinical-stage startup company which develops best-in-class drugs on the STING pathway to activate the innate immune system to fight back infectious pathogens or cancer. It was founded in 2016 and is focused on the development of STING agonists in cancer.

SUPERBRANCHE : Nanomedicine as a breakthrough to treat cancer We bring answers to the following issue: intratumoral injection of nanomaterials implying both accessibility and detection of the tumor beforehand. We position ourselves as a producer dedicated to the synthesis of architectured nanomaterials as simple as possible and of controlled size. Our modular technology platform presents both therapeutic and diagnosis applications. It consists in a magnetic nanoparticle coated by a tailor made branched architecture. Thanks to their optimized shape and stability, our compounds are well tolerated and can be administered intravenously, thus helping to the early detection and treatment of metastases. The main advantage of the SUPERBRANCHE technology stem from our specific processes and synthesis know-how which are at the heart of our innovations. Superbranche is a Biotechnology company characterized by two main activities: - the sale of dendrimers and nanoparticles as research products to any laboratory in the field of nanomedicine - conducting development partnerships to bring to the clinics targeted diagnostic and image-guided therapy nanomaterials based on its proprietary technology.

Surgimab SAS is a biotechnology company based out of Montpellier, Languedoc-Roussillon, France.

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy.

Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.

“Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis. Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines. Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective transfection mechanism to elicit a potent and targeted immune response previously unseen.

Theravia is an international pharmaceutical laboratory based in France, focusing on rare, neglected, and debilitating diseases. Formed from the merger of Addmedica and CTRS, the company operates in over 35 countries across five continents. Theravia is dedicated to addressing unmet medical needs through innovative therapies and strategic partnerships. The company develops, registers, and promotes specialized medical products, including pharmaceuticals, medical devices, and diagnostics. Their portfolio features six registered products, such as Siklos for sickle cell disease and Orphacol for genetic disorders affecting bile acid production. Theravia collaborates with research groups and healthcare institutions to enhance disease awareness and improve treatment accessibility for over 15,000 patients globally. With more than 20 years of experience in rare disease therapeutics, Theravia emphasizes patient-centric solutions and adaptive strategies. The company has established over 30 partnerships worldwide, reflecting its commitment to advancing healthcare for those with rare metabolic, hematologic, and immunologic conditions.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Cancer immunotherapy Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.

Tribun Health powers the digital transformation of cancer diagnosis by designing innovative solutions. These solutions enable the management, analysis and sharing of cellular images for both diagnostic laboratories and pharmaceutical/biotech companies. The company offers customized support in digital pathology, focused on the customer’s expectations. In the field of image analysis, our solutions are based on the latest innovations in terms of artificial intelligence, notably deep and machine learning algorithms. These tools support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients. In the field of sharing, our solutions implement full web tools to support our customers in their telepathology, teaching or multi-centric clinical validation activities.

Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response. CD31 belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Developing agonists for ‘ITIM receptors’ has the potential to restore the immune balance without immunosuppression. Tridek-One demonstrated the ability of CD31 to modulate cells from both the adaptive and innate immune systems which makes it a unique and versatile target across diverse autoimmune and inflammatory disorders. Our company is financed by leading European investors and led by an experienced management team supported by renowned advisors.

Université de Bordeaux is a higher education institution offering a wide range of academic programs and conducting research.

Urgo Medical is the wound-healing division of URGO group. Every day our 1600 employees are passionate about creating, developing and promoting highly innovative dressings and global solutions to heal people suffering from wounds. Our mission, as The Healing Company, is to make a significant difference for patients, healthcare professionals and the healthcare systems. In order to fulfil our mission: • Patient is at the heart of everything we do. • We keep innovating to develop the best in class solutions. • We have a pioneer and entrepreneurial mindset and we dare to take risks to find new solutions. This is why we are different. This is why we can make a difference. Our innovation and conqueror mindset enables us to be a dynamic Advanced Wound Care company.

UroMems was founded in 2011 and focuses on designing, developing and commercializing active implantable medical devices. The company is based at the heart of the French Silicon Valley, in the Sophia Antipolis technopark, near Nice, France.

Pioneer and expert in blood and tissue microbiota, Vaiomer carries out microbiota studies, in the fields of human and animal health, for preclinical and clinical research, CROs, dermocosmetics, nutraceuticals and pharmaceutical / biotech companies. We perform microbiota studies from a very wide variety of biological samples (blood, adipose tissue, biopsies, tumors, and more classically skin, saliva, faeces, etc.): DNA extraction, quantification by qPCR, sequencing metagenomics, Bioinformatics, Biostatistics. Upstream and downstream of the studies: support for the experimental design and the drafting of study protocols, then for the interpretation and valuation of the results. The role of tissue and blood microbiomes in systemic inflammation is studied in a wide variety of pathologies: https://vaiomer.com/microbiome-applications/ Microbiota can interact with compounds. The study of the action of a compound on the microbiota makes it possible to characterize the modulating, protective or toxic effects of the microbiota on the compound, or of the compound on the microbiota. Taking into account variations in the microbiota also makes it possible to derisk the translation from the animal model to humans: it is a new source of biomarkers of the therapeutic response (responders / non-responders). We are an expert multidisciplinary team (Scientific / Microbiota, Molecular Biology, Bioinformatics and Biostatistics), have a unique technology for samples of low bacterial biomass and a molecular biology laboratory that can process samples from infected subjects (COVID , HIV...)

Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today, a single-shot chikungunya vaccine candidate and an inactivated vaccine candidate against COVID-19.

Vaxinano is a biotechnology company specializing in the pre-clinical and clinical development of human and veterinary vaccines. Vaxinano was created in 2016, based on 30 years of research and clinical trials in vaccinology using technology patented by Pr. Didier Betbeder. Our approach is based on a unique and innovative antigen delivery system using bio-compatible, adjuvant-free and safe-by-design nanoparticles.

VAXON Biotechis a private company, located in Paris – France, that was founded in 2004. The company develops innovative therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using itsproprietary technology of optimized cryptic peptides.

Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta's DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters. The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space. Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

About us Since its creation in 1962, continuous technological and market research, implementation of latest technology at all levels, dedication to customer satisfaction and high quality and reliability standards are the key factors in Vygon's growth. Vygon's name has become synonymous with quality and reliability in the field of single-use medical and surgical products. Know-how Our industrial culture grew along with the company. We now have 11 factories worldwide, and we manufacture some 210 million medical devices every year. 9 of our factories are located in Europe, including 5 in France. We inspect the entire production line, from procurement of raw materials through to distribution logistics. We guarantee the traceability of our products and quality control. Every pack we deliver results from the know-how and commitment of multidisciplinary teams that work together and learn from each other - the driving force behind Vygon. Conceived and designed by our engineers and technicians and manufactured in one of our 11 plants, Vygon products meet ISO 13485 standards as well as the environmental ISO standard 14001. 60 years after its creation, our group now has the support of 26 subsidiaries and 11 production sites, including 8 in Europe. Thanks to the hard work of its 2,619 employees, Vygon manufactures nearly 210 million medical devices every year.

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies. Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported by French Tech 2030 program and recently joined the Bayer Co.Lab in Cambridge, MA, and Ginkgo Bioworks' Technology Network, marking major milestones in our international expansion.

Xegen is a bioinformatics company specialized in Next Generation Sequencing (NGS) data analysis. We provide support for our customers or partners in their NGS data processing issues, through specific, automated, high added value bioinformatics analyzes. Xegen is developing Polypheme a bioinformatics suite dedicated to complex genes analysis (polymorphisms detection or allelic types). Polypheme analysis includes in particular HLA Typing, classic (HLA-A, -B, -C, DRB1, DQB1) and not classic genes (HLA-E, -F, -G, -H). Polypheme is also used to discover new alleles.

XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in several indications. Our patented technological platform is built on our expertise in immunology and therapeutics. We develop innovative approaches in immunotherapy with our platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are addressing major therapeutic needs in various domains, including oncology, immunosuppression, viral and bacterial infections. XENOTHERA’s platform allows short-time development thanks to our validated saled-up GMP platform, our in-house bioproduction facility, our clinical experience (400 patients have received GH-pAb today), our mastery of antigens and our regulatory experience. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market, XAB05, a preventive anti- multidrug resistant bacteria GH-pAb, XAV19 an anti-COVID antibody dedicated to patients with moderate disease. XENOTHERA has accumulated preclinical evidence for the therapeutic effect of its oncology GH-pAbs. Two products will be in clinic in oncology in 2023, XON7, its lead pan-cancer targeting solid tumors and LIS22 in peripheral T-Cell lymphoma.

Ziwig ® is a French company whose ambition is to improve women’s health through a holistic approach and the development of products, services and a care ecosystem guided by science and the unique biology of each individual. This approach is supported by ongoing research excellence and is based on the close collaboration of medical experts and engineers specialized in cutting- edge technologies such as artificial intelligence and Next Generation human RNA Sequencing. Its functioning is based on an ecosystem, driven by the quest for excellence and patient centered, that uses disruptive technologies. This contributes to the emergence of precision medicine that is individualized, predictive and participatory, serving women’s well-being and quality of life. Ziwig’s work has resulted in several publications that have appeared in international peer-reviewed scientific journals such as diagnostics, Nature scientific reports and Journal of Clinical Medicine. Follow us on Instagram : https://www.instagram.com/ziwigfrance/